According to Zacks, “Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. “
Separately, Cantor Fitzgerald reiterated an overweight rating on shares of Theseus Pharmaceuticals in a report on Friday, April 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, Theseus Pharmaceuticals has an average rating of Buy and a consensus price target of $22.40.
Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). As a group, analysts expect that Theseus Pharmaceuticals will post -1.17 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of THRX. Boxer Capital LLC purchased a new stake in shares of Theseus Pharmaceuticals during the fourth quarter worth $11,311,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter worth $9,657,000. Omega Fund Management LLC acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter worth $9,022,000. Nextech Invest AG acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter worth $7,751,000. Finally, BlackRock Inc. acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter worth $6,761,000. 90.00% of the stock is currently owned by institutional investors and hedge funds.
About Theseus Pharmaceuticals (Get Rating)
Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.
- Get a free copy of the StockNews.com research report on Theseus Pharmaceuticals (THRX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theseus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.